AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This milestone marks the clinical advancement of a novel therapeutic approach designed...
Zhongchao Inc. Announces $5.0 Million Registered Direct Offering
SHANGHAI, July 23, 2026 /PRNewswire/ -- Zhongchao Inc ("Zhongchao" or the "Company") (NASDAQ: ZCMD), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 4,545,455 of the Company's Class A Ordinary Shares, par value $0.744 per share (the "Shares") (or pre-funded warrants in lieu thereof) at...
NYSE Content Update: Fourth Annual AI x Bio Summit to Commence at the NYSE
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Similarweb tracking earnings season...
PUBLIC TRUST IN HEALTH INNOVATION IS SHAPED MORE BY MINDSET THAN DEMOGRAPHICS, DNV RESEARCH FINDS
OSLO, Norway, July 23, 2026 /PRNewswire/ -- Public trust in health innovation may be less predictable than healthcare organizations assume, according to new research from DNV, the independent assurance and certification provider. New global research report: The Future of Health A global survey of 12,500 people across 17 countries...
Moa Technology raises Series C round co-led by Oxford Science Enterprises and Supernova Invest
OXFORD, England, July 23, 2026 /PRNewswire/ -- Moa Technology ("Moa"), an agricultural biotechnology company focused on discovering novel mode of action herbicides, announces a £22.2 million Series C financing round, co-led by Oxford Science Enterprises ("OSE") and Supernova Invest ("Supernova"). Moa Technology CEO Dr Virginia Corless in the company's glasshouse research facility in North Yorkshire,...
AXA Survey Reveals Menopause Awareness Gap Among Hong Kong Working Women
Misconceptions deny women a critical ten-year window for health management, highlighting urgent need for greater awareness and stronger employer care HONG KONG, July 23, 2026 /PRNewswire/ -- Findings from the AXA Hong Kong Female Health Survey 2026 ("the Study") conducted by AXA Hong Kong and Macau ("AXA"), reveal significant gaps in awareness and understanding of menopause among working women in...
Haisco’s Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China (NMPA) for the treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are complement-inhibitor-naïve. This is Haisco's fifth innovative drug approved for...
Registration Now Open: Free Global Webinar on Dual-HA Biostimulation Featuring Live Clinical Demonstration
SEOUL, South Korea, July 23, 2026 /PRNewswire/ -- HIGHER Corporation has opened registration for the 2026 HILO WAVE® Global Webinar, a complimentary educational webinar designed exclusively for licensed physicians and healthcare professionals practicing aesthetic medicine. The live webinar will take place on Wednesday, August 12, 2026, at 8:00 p.m. Korea Standard Time (11:00 GMT) and will be conducted entirely...
GHIT Fund Invests Approx. JPY 140 Million in a Portable Rapid Diagnostic System for Ebola Disease in a Joint Project Between Osaka Metropolitan University, K.K. DNAFORM, and INRB
TOKYO, July 23, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of JPY 140 million (approximately USD 862,000) in a project to develop a portable rapid diagnostic system for Ebola disease. The system is being jointly developed by Osaka Metropolitan University, K.K. DNAFORM (DNAFORM), and the National Institute for Biomedical Research (INRB)...
Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases
Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice® transgenic mouse technology platform for translational antibody research CAMBRIDGE, Mass., July 23, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, today announced a research collaboration with the Medical University...
